Estimating Time to ESRD in Children With CKD

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10393477" target="_blank" >RIV/00216208:11130/18:10393477 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10393477

Výsledek na webu

<a href="https://doi.org/10.1053/j.ajkd.2017.12.011" target="_blank" >https://doi.org/10.1053/j.ajkd.2017.12.011</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1053/j.ajkd.2017.12.011" target="_blank" >10.1053/j.ajkd.2017.12.011</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Estimating Time to ESRD in Children With CKD

Popis výsledku v původním jazyce

Rationale &amp; Objective: The KDIGO (Kidney Disease: Improving Global Outcomes) guideline for chronic kidney disease (CKD) presented an international classification system that ranks patients&apos; risk for CKD progression. Few data for children informed guideline development. Study Design: Observational cohort study. Settings &amp; Participants: Children aged 1 to 18 years enrolled in the North American Chronic Kidney Disease in Children (CKiD) cohort study and the European Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients (ESCAPE) trial. Predictor: Level of estimated glomerular filtration rate (eGFR) and proteinuria (urine protein-creatinine ratio [UPCR]) at study entry. Outcome: A composite event of renal replacement therapy, 50% reduction in eGFR, or eGFR &lt; 15 mL/min/1.73 m 2 . eGFR was estimated using the CKiD-derived &quot;bedside&quot; equation. Analytical Approach: Accelerated failure time models of the composite outcome using a conventional generalized gamma distribution. Likelihood ratio statistics of nested models were used to amalgamate levels of similar risk. Results: Among 1,232 children, median age was 12 (IQR, 8-15) years, median eGFR was 47 (IQR, 33-62) mL/min/1.73 m 2 , 60% were males, and 13% had UPCRs &gt; 2.0 mg/mg at study entry. 6 ordered stages with varying combinations of eGFR categories (60-89, 45-59, 30-44, and 15-29 mL/min/1.73 m 2 ) and UPCR categories (&lt;0.5, 0.5-2.0, and &gt;2.0 mg/mg) described the risk continuum. Median times to event ranged from longer than 10 years for eGFRs of 45 to 90 mL/min/1.73 m 2 and UPCRs &lt; 0.5 mg/mg to 0.8 years for eGFRs of 15 to 30 mL/min/1.73 m 2 and UPCRs &gt; 2 mg/mg. Children with glomerular disease were estimated to have a 43% shorter time to event than children with nonglomerular disease. Cross-validation demonstrated risk patterns that were consistent across the 10 subsample validation models. Limitations: Observational study, used cross-validation rather than external validation. Conclusions: CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children. (C) 2018 National Kidney Foundation, Inc.

Název v anglickém jazyce

Estimating Time to ESRD in Children With CKD

Popis výsledku anglicky

Rationale &amp; Objective: The KDIGO (Kidney Disease: Improving Global Outcomes) guideline for chronic kidney disease (CKD) presented an international classification system that ranks patients&apos; risk for CKD progression. Few data for children informed guideline development. Study Design: Observational cohort study. Settings &amp; Participants: Children aged 1 to 18 years enrolled in the North American Chronic Kidney Disease in Children (CKiD) cohort study and the European Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients (ESCAPE) trial. Predictor: Level of estimated glomerular filtration rate (eGFR) and proteinuria (urine protein-creatinine ratio [UPCR]) at study entry. Outcome: A composite event of renal replacement therapy, 50% reduction in eGFR, or eGFR &lt; 15 mL/min/1.73 m 2 . eGFR was estimated using the CKiD-derived &quot;bedside&quot; equation. Analytical Approach: Accelerated failure time models of the composite outcome using a conventional generalized gamma distribution. Likelihood ratio statistics of nested models were used to amalgamate levels of similar risk. Results: Among 1,232 children, median age was 12 (IQR, 8-15) years, median eGFR was 47 (IQR, 33-62) mL/min/1.73 m 2 , 60% were males, and 13% had UPCRs &gt; 2.0 mg/mg at study entry. 6 ordered stages with varying combinations of eGFR categories (60-89, 45-59, 30-44, and 15-29 mL/min/1.73 m 2 ) and UPCR categories (&lt;0.5, 0.5-2.0, and &gt;2.0 mg/mg) described the risk continuum. Median times to event ranged from longer than 10 years for eGFRs of 45 to 90 mL/min/1.73 m 2 and UPCRs &lt; 0.5 mg/mg to 0.8 years for eGFRs of 15 to 30 mL/min/1.73 m 2 and UPCRs &gt; 2 mg/mg. Children with glomerular disease were estimated to have a 43% shorter time to event than children with nonglomerular disease. Cross-validation demonstrated risk patterns that were consistent across the 10 subsample validation models. Limitations: Observational study, used cross-validation rather than external validation. Conclusions: CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children. (C) 2018 National Kidney Foundation, Inc.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Kidney Diseases

ISSN

0272-6386

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

783-792

Kód UT WoS článku

000433028100006

EID výsledku v databázi Scopus

2-s2.0-85045892828